Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
Holding NVAX?
Track your performance easily
NVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.53 - $23.86
Previous Close$9.44
Volume6.50M
Average Volume (3M)6.12M
Market Cap
$1.46B
Enterprise Value$643.74M
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$233.25M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Nov 12, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding160,093,639
10 Day Avg. Volume4,436,305
30 Day Avg. Volume6,123,748
Standard Deviation0.51
R-Squared0.05
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-3.32
Price to Sales (P/S)1.93
Price to Cash Flow (P/CF)1.20
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.65
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda-9.78
Forecast
1Y Price Target
$16.80Price Target Upside87.50% Upside
Rating ConsensusHold
Number of Analyst Covering5
Novavax News
PremiumCompany Announcements
Novavax Settles Vaccine Supply Agreement Dispute
Bulls Say, Bears Say
Bulls Say
Business StrategyAnalyst reiterates a Buy rating on Novavax, Inc. due to a major business model change underway, focusing primarily on R&D with potential value-creating partnerships.
Market PerformanceStrong early launch trends indicate that the lower end of the U.S. commercial sales guide is attainable, with revised estimates exceeding consensus expectations.
Product DevelopmentThe initiation of Phase III CIC and flu trial is seen as a key catalyst, with quick enrollment that could yield registration-enabling data by mid-2025.
Bears Say
COVID-19 Vaccine Market UncertaintyThe outlook for the COVID-19 vaccine market in later years remains murky and the rate at which sales might grow remains increasingly uncertain.
Financial Performance And Revenue ForecastsAnalyst believes current share levels overvalue the discounted forecasts of associated royalty revenue streams to the company.
Regulatory And Clinical ChallengesRegulatory setback having more of an impact to sentiment than longer-term fundamentals.
---
Ownership Overview
0.24% Insiders
11.44% Mutual Funds
7.15% Other Institutional Investors
62.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $3.53 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 12, 2024 which is in 3 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 08, 2024. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.67 by -$0.68.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -$0.83.
How many shares outstanding does Novavax have?
Novavax has 160,093,640 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.99 in its last earnings report, missing expectations of $1.67. Following the earnings report the stock price went up 9.057%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 33M.
---
Novavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.80 (87.50% Upside)
$16.80 (87.50% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 89%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 430.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.93%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVAX Company Deck
---
NVAX Earnings Call
Q2 2024
0:00 / 0:00
---
NVAX Stock 12 Month Forecast
Average Price Target
$16.80
▲(87.50% Upside)
Technical Analysis
Best Analysts Covering NVAX
1 Year
1 Year Success Rate
20/35 ratings generated profit
1 Year Average Return
+158.01%
reiterated a buy rating 6 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +158.01% per trade.
---